References 1. McClung MR, Miller PD, Brown J, Zanchetta J, Bolognese MA, Benhamou C-L, Balske A, Burgio D, Sarley J, Recker RR (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet in the treatment of postmenopausal osteoporosis. Osteoporos Int 23(1):267–276PubMedCrossRef 2. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75–85PubMedCrossRef 3. Fleisch HA (1997) Bisphosphonates: preclinical

aspects and use in osteoporosis. Ann Med 29(1):55–62PubMedCrossRef 4. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 4(5):488–492 5. Cramer JA, Amonkar

MM, selleck products Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef 6. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022PubMedCrossRef 7. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44(1):153–159PubMedCrossRef Liothyronine Sodium BX-795 nmr 8. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics

31(1):103–115PubMedCrossRef 9. Genant HK, Wu CY, Van Kuik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMedCrossRef 10. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3(2):133–144PubMedCrossRef 11. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352PubMedCrossRef 12. Reginster JY, Minne HW, Sorensen O et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMedCrossRef 13. McClung MR, Dinaciclib mouse Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMedCrossRef 14.